CLINICAL TRIALS PROFILE FOR CISATRACURIUM BESYLATE
✉ Email this page to a colleague
All Clinical Trials for Cisatracurium Besylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02508857 ↗ | Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries | Completed | Instituto do Cancer do Estado de São Paulo | Phase 4 | 2010-01-01 | Magnesium sulfate has been reported to improve postoperative pain, but evidence is still controversial. Some studies demonstrated benefits while others concluded that there is no efficacy. Aim: the aim of the study was to compare the effect of intravenous infusion of magnesium sulfate to ketorolac during laparoscopic gynecologic oncology surgeries. Methods: We designed a double-blind randomized controlled trial that compared intravenous magnesium sulfate to ketorolac and saline solution in postoperative pain, morphine consumption and opioid related side effects. |
| NCT02509078 ↗ | Reevaluation Of Systemic Early Neuromuscular Blockade | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 2016-01-04 | This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged. |
| NCT02509078 ↗ | Reevaluation Of Systemic Early Neuromuscular Blockade | Completed | Massachusetts General Hospital | Phase 3 | 2016-01-04 | This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged. |
| NCT02588118 ↗ | Gender and PK-PD of Propofol and Cisatracurium | Completed | Medical University of Graz | 2010-01-01 | In recent years it has become clear that gender differences exist both in the pharmacokinetics and the pharmacodynamics of drugs related to the practice of anesthesia. Differences in pharmacokinetics are more straightforward to study than differences in clinical effects. However, isolated pharmacokinetic data are of less value if they are not accompanied by measurements of clinical effects. Males are more sensitive than females to propofol. It may therefore be necessary to decrease the propofol dose by 30-40% in males. Females have 20-30% greater sensitivity to the muscle relaxant effects. | |
| NCT02820025 ↗ | The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence | Unknown status | General Hospital of Ningxia Medical University | N/A | 2015-10-01 | The current study is designed to investigate the difference of plasma orexin A levels between doxapram group and controlled group at emergence time from sevoflurane-remifentanil anesthesia who will undergo elective lumbar surgery. |
| NCT03025295 ↗ | The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine | Completed | General Hospital of Ningxia Medical University | N/A | 2017-02-01 | The current study is designed to investigate the difference of plasma orexin A levels between Dexmedetomidine group and controlled group at emergence time from total intravenous anesthesia who will undergo elective lumbar surgery. |
| NCT03337373 ↗ | The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium | Completed | Mahidol University | Phase 4 | 2017-12-15 | Pathophysiological changes influenced by multiple factors in critically ill patients, has a significant impact on pharmacokinetics (PK) and pharmacodynamics (PD) of cisatracurium. In order to understand better and find an appropriate dosing regimen, the purpose of this study is to investigate the PK and PD of a loading dose cisatracurium in critically ill patients. Cisatracurium, nondepolarizing neuromuscular blocking agents (NMBAs), are commonly used in intensive care units because of a lesser effect on hemodynamic parameters and a reduction in mortality rate in ARDS patients. Loading dose recommended in clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient is 0.1-0.2 mg/kg. Then, maintenance dose of 1-3 mcg/kg/min is followed regarding indications, such as ARDS. However, this recommended loading dose might not be adequate in critically ill patients, the study in this specific population might be needed. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cisatracurium Besylate
Condition Name
Clinical Trial Locations for Cisatracurium Besylate
Trials by Country
Clinical Trial Progress for Cisatracurium Besylate
Clinical Trial Phase
Clinical Trial Sponsors for Cisatracurium Besylate
Sponsor Name
